Rhabdoid tumors (RTs) are aggressive and currently incurable pediatric malignancies. INI1/hSNF5 is a tumor suppressor biallelically inactivated in RTs. Our previous studies have indicated that cyclin D1 is a key downstream target of INI1/hSNF5 and genesis and/or survival of RTs in vivo is critically dependent on the presence of cyclin D1. In this report, we have tested the hypothesis that therapeutic targeting of cyclin D1 is an effective means of treating RTs. We found that RNA interference of cyclin D1 in rhabdoid cells was sufficient to induce G1 arrest and apoptosis. Furthermore, we found that pharmacological intervention with low micromolar concentrations of N-(4-hydroxyphenyl)retinamide (4-HPR), which downmodulates cyclin D1, induced G1 arrest and apoptosis in rhabdoid cell lines. 4-HPR in combination with 4-hydroxy-tamoxifen (4OH-Tam), synergistically inhibited survival as well as anchorage-dependent and -independent growth of rhabdoid cells and caused synergistic induction of cell cycle arrest and apoptosis. 4-HPR and tamoxifen exhibited synergistic growth inhibition of RTs in xenograft models in vivo. The effects of combination of drugs were correlated to the depletion of cyclin D1 levels both in in vitro and in vivo tumor models. These results demonstrate that 4-HPR and tamoxifen are effective chemotherapeutic agents for RTs. We propose that downmodulation of cyclin D1 is a novel and effective therapeutic strategy for RTs.
Introduction
Rhabdoid tumors (RTs) of the kidney (malignant rhabdoid tumors (MRT)), brain (atypical teratoid and rhabdoid tumors (AT/RT)), and soft tissues are aggressive pediatric malignancies Packer et al., 2002) . Prognosis for infants with these tumors is poor and approximately 80% of affected children die within 1 year of diagnosis despite intensive treatment . The majority of RTs harbor critical inactivating biallelic alterations in the INI1/hSNF5 gene, a tumor suppressor and a component of chromatin remodeling SWI/SNF complex (Versteege et al., 1998) . Mechanisms of INI1/hSNF5-mediated tumor suppression include induction of G1 arrest and control of the mitotic spindle checkpoint (Ae et al., 2002; Betz et al., 2002; Versteege et al., 2002; Zhang et al., 2002; Vries et al., 2005) .
Our previous studies have demonstrated that cyclin D1 is a critical downstream effector of INI1/hSNF5. We found that INI1/hSNF5 directly represses cyclin D1 transcription and that cyclin D1 expression from a heterologous promoter is sufficient to overcome INI1/hSNF5-mediated cell cycle arrest (Zhang et al., 2002) . Cyclin D1 is derepressed in human and mouse INI1À/À RTs (Zhang et al., 2002; Tsikitis et al., 2005) . In addition, genetic ablation of cyclin D1 is sufficient to abrogate the genesis of RTs in vivo mouse models (Tsikitis et al., 2005) . These studies suggest that RTs are critically dependent on the presence of cyclin D1 for genesis and/or survival.
Cyclin D1 has multiple roles during cell cycle, propagation and tumorigenesis (Fu et al., 2004) . It associates with cyclin-dependent kinases, cdk4 and cdk6, leading to the phosphorylation and inactivation of retinoblastoma (Rb) protein. It sequesters p27, releasing CyclinE to further inactivate Rb, resulting in G1 to S transition. Cyclin D1 modulates the activity of several transcription factors in a cdk-independent manner, which may be important for its function in tumor cells. There are two isoforms of cyclin D1, D1a and D1b, which confer differential transformation ability to mammalian cells.
Based on the exquisite dependency of RTs on cyclin D1, we hypothesized that inhibition of cyclin D1, its activity or its pathway may be a good therapeutic strategy for treatment of children with RTs. In this report, we have tested this hypothesis in rhabdoid cells and tumors by: (i) knocking down cyclin D1 by RNA interference, and (ii) pharmacologically downmodulating cyclin D1 levels. At this point it is not clear what function or activity (i.e. the cdk-dependent or -independent function or isoform-specific activity) of cyclin D1 is required for rhabdoid tumorigenesis. Owing to this reason, and since there are no drugs that selectively target cyclin D1, we have begun to test the effect of chemotherapeutic agents that as a part of their mechanism, directly or indirectly downmodulate cyclin D1 levels.
N-(4-hydroxyphenyl)retinamide (4-HPR or Fenretinide) is a synthetic retinoid that has a low potential for cytotoxicity, and in vitro suppresses tumor cell growth and induces apoptosis at clinically achievable concentrations (Reynolds and Lemons, 2001 ). Overexpression of cyclin D1 sensitizes certain cancer cells to 4-HPR (Pirkmaier et al., 2003) , and 4-HPR affects the transcription as well as the protein stability of cyclin D1 (DiPietrantonio et al., 1998; Dragnev et al., 2004) . In addition, 4-hydroxy-tamoxifen (4OH-Tam) synergizes with 4-HPR to induce apoptosis (Maurer et al., 2000; Wang et al., 2003) . Suppression of tumor growth by 4OH-Tam has been associated with downmodulation of cyclin D1 (Jang et al., 2001) . 4OH-Tam induces the expression of p21
Waf1 and p27
Kip1
, which block the activating effect of cyclin D1 (Lee et al., 1999b) . In this report, we have tested the ability of 4-HPR and 4OH-Tam to inhibit the growth of rhabdoid cells in vitro and tumors in vivo. Our results demonstrate that rhabdoid cells and tumors are sensitive to these drugs, and sensitivity is correlated with downmodulation of cyclin D1. Furthermore, inhibiting cyclin D1 by RNA interference was sufficient to induce cell cycle arrest and apoptosis in rhabdoid cells. These results suggest that inhibiting cyclin D1 is a novel and potentially effective targeted therapy for RTs.
Results
Effect of cyclin D1 siRNA on proliferation of rhabdoid cells Mouse knockout studies indicated that deletion of cyclin D1 abrogates the genesis of RTs (Tsikitis et al., 2005) . To test if cyclin D1 itself is required for the survival of RT cell lines, we transfected a rhabdoid cell line with small interfering RNA oligonucleotides against cyclin D1. Immunoblot analysis of the total proteins isolated from the transfected cells indicated the downmodulation of cyclin D1 protein in test samples compared to that transfected with control, scrambled siRNA ( Figure 1a ). FACS analysis of the diploid population, 4 days after transfection of cyclin D1 siRNA, indicated a clear induction of G1 arrest as compared to the control (Figure 1b and c) . Furthermore, downmodulation of cyclin D1 by siRNA resulted in up to 13-fold increase in the sub-G1 cells (Figure 1d ) (Po0.05). On the contrary, there was no difference in the growth or cell cycle of 293T cells transfected with cyclin D1 siRNA, indicating that the observed effects were specific to rhabdoid cells (data not shown). These results clearly indicated that downmodulation of cyclin D1 alone is sufficient to cause cell cycle arrest and induce apoptosis in rhabdoid cells, consistent with the hypothesis that RTs are dependent on cyclin D1 for their survival. (Figure 2e and f). These data suggested that 4-HPR treatment results in induction of G1 arrest and apoptosis in rhabdoid cells.
4OH-Tam augments the 4-HPR-induced growth arrest of RT cells
Clinical studies have demonstrated that 4-HPR administration results in variable plasma and tissue accumulation of the drug (up to 2 mM), which is below the observed IC 50 's for rhabdoid cells (Reynolds, 2000) . Therefore, we considered using a combination of drugs to reduce the required effective dose of 4-HPR. It was reported that 4OH-Tam synergizes with 4-HPR in inhibiting the growth of several cancer cells in vitro (Maurer et al., 2000) . As stated earlier, both 4-HPR and 4OH-Tam appear to decrease cyclin D1 levels or activity by various mechanisms (DiPietrantonio et al., 1998; Lee et al., 1999a; Jang et al., 2001; Dragnev et al., 2004 ). Therefore, we tested the effect of combination of 4OH-Tam and 4-HPR on the survival of MON, the least sensitive rhabdoid line, by using MTS assays.
Consistent with the previous findings, treatment of MON cells with 10 mM or less of 4OH-Tam alone did not drastically inhibit the survival, whereas concentrations above 10 mM resulted in rapid cell death ( Figure 3a ) (Koshida et al., 2002 ). Therefore, we tested the effect of combination of 4-HPR with 10 mM 4OH-Tam for various times of exposure ( Figure 3b ). While combination treatment for 24-48 h only slightly decreased the IC 50 value, at 72 h, the IC 50 and IC 99 of 4-HPR were dramatically reduced to B2.0 and 12.5 mM, respectively, indicating that, with longer time of exposure, these two drugs synergistically inhibit rhabdoid cell survival ( Figure 3b ). Further experiments were performed using varying concentrations of 4OH-Tam and 4-HPR, with exposure times of 72 and 98 h (Figure 3c We determined fractional survival (Fa) and combination index (CI) using the Chou and Talaley method to determine the synergy. The results of this analysis indicated that the combination of 4-HPR and 4-OHTam was synergistic as their CI values for the affected fraction of cells ranging from 0.2 to 0.9 was significant (o1, mean CI for this range is 0.75, Figure 3e ).
4OH-Tam and 4-HPR combination synergistically inhibits anchorage-dependent and -independent growth of rhabdoid cell lines
We carried out a series of additional experiments with a combination of the two drugs to determine their effect on the survival and transformation ability of rhabdoid cells. The results of a clonogenic assay measuring the uptake of methylene blue dye by the live cells indicated that while 3.125 mM 4-HPR treatment reduced methylene blue uptake to 78% (s.d. 710%), combination treatment with 10 mM 4-OH-Tam reduced it to 39% (s.d. 71%) of that of vehicle-treated cells (Po0.0001). In addition, while 12.5 mM of 4-HPR exposure reduced the methylene blue uptake to 28% of the control (s.d. 72%), the combination of 12.5 mM 4-HPR and 10 mM 4OH-Tam resulted in complete elimination of live cells ( Figure 4B , panel f; Po0.0001) ( Figure 4A and B).
The effect of drugs was also assessed on anchoragedependent monolayer colony formation assays. The colony formation ability of MON cells was assessed either in the continuous presence (assay 1) or absence (assay 2) of drugs after the initial exposure of cells to drugs for 48 h. At 30 days after culturing, MON cells treated with 12.5 mM 4-HPR exhibited a dramatic reduction in cell proliferation, which was further augmented in combination with 4OH-Tam ( Figure 4C ). Furthermore, maintenance of the cells in the presence of 12.5 mM 4-HPR and 4OH-Tam resulted in complete cell killing ( Figure 4C , panel e), indicating that prolonged incubation with the combination of the two drugs is effective in drastically reducing survival of rhabdoid cells.
We further tested the ability of drugs to inhibit the anchorage-independent growth by using the soft agar assay. Since the drugs were not replenished in the agar medium, the colony formation is a stringent assessment of the drug effect after single exposure. The results of these assays indicated that combination of 4-HPR and 4OH-Tam yielded significantly fewer colonies (52713%), which are of smaller size than those obtained in either 4-HPR-(8378%) or 4OH-Tam- Figure 4D ). These results indicated that the combination of 4OH-Tam and 4-HPR effect is robust and is strongly effective in reducing the survival and growth of rhabdoid cells by various assays.
Combination drug treatment synergistically induces cell cycle arrest and apoptosis in rhabdoid cells To determine if the synergistic inhibition of rhabdoid cell growth by combination of 4-HPR and 4OH-Tam is correlated to the induction of cell cycle arrest and apoptosis, the drug-treated cells were subjected to FACS analysis ( Figure 5a and Table 1 ). The results of FACS analysis indicated that there was an increase in G1-phase cells and a significant decrease in S-phase cells with increasing concentration of 4-HPR (Po0.001). 4OH-Tam had effects that were similar to that of 12.5 mM 4-HPR ( Figure 5a and Figure 5a and Table 1 ). These results suggested that the combination drug treatment affects G1, S and G2 profiles of rhabdoid cells. Furthermore, the percentage of sub-G1 cells increased with increasing concentrations of 4-HPR, which was further augmented in the presence of 4OH-Tam ( Figure 4B ). These results indicate that the combination of drugs synergistically induces cell cycle arrest and apoptosis in rhabdoid cells.
To determine the mechanism of induction of cell death, luminescence-based caspase-3 and -7 activity assays were performed on drug-treated rhabdoid cells The inset represents results of immunoblot analysis of cell pools to determine the total levels of cyclin D1 protein in these cells using a-cyclin D1 antibody that recognizes the two isoforms (neomarkers Ab-1, DCS-6). The same blot was stripped and re-probed with a-actin antibody as a loading control. Note the presence of a doublet indicating either cyclin D1a ('a') or cyclin D1b ('b') isoform. Figure 4C ). The results indicated that caspase-3 and -7 activities reached maximal levels when the cells were treated with 4-HPR alone at 25 mM. However, in the presence of 4OH-Tam, maximum levels of caspase-3 and -7 activity were reached even at 12.5 mM concentrations ( Figure 5c ). These results indicated that induction of apoptosis in part by the combination of drugs is by activation of caspases.
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4-HPR and 4OH-Tam treatment downmodulates cyclin D1 levels in rhabdoid cells
Since rhabdoid cells and tumors appear to be critically dependent on the presence of cyclin D1 (Tsikitis et al., 2005) , we determined the effect of 4-HPR and 4OH-Tam on cyclin D1 levels. Immunoblot analysis indicated that, at 48 h of exposure, cyclin D1 levels were drastically reduced in the presence of 6 mM 4-HPR (Figure 5d ). 4OH-Tam treatment alone reduced the levels of cyclin D1 (Figure 5d , lane 6). Furthermore, in the presence of 4OH-Tam, even the lowest concentration of 4-HPR (B3 mM) was sufficient to drastically reduce the levels of cyclin D1 (Figure 5d , lane 7). These results indicated that 4-HPR and 4OH-Tam combination treatment results in synergistic inhibition of cyclin D1 levels and is correlated with the biological effects of the drug.
Expression of Cyclin D1 from a heterologous promoter renders the rhabdoid cells less susceptible to 4-HPR and 4OH-Tam treatment
It has been reported that 4-HPR and 4OH-Tam downmodulate transcription of Cyclin D1 (Panigone et al., 2000) . Therefore, it is possible that the expression of Cyclin D1 from a heterologous promoter that is not subjected to the repression by these drugs may render the rhabdoid cells less susceptible for the drug-mediated cytotoxicity. Since there are two isoforms of Cyclin D1, 'a' and 'b', and since the expression of the 'b' genotype has been correlated to poor prognosis in several malignancies (Le Marchand et al., 2003) , we tested the effect of expression of each one of these isoforms. Pools of MON cells stably expressing either Cyclin D1a or D1b were generated using retroviral vector-mediated transduction. Western analysis of these pools of cells using Cyclin D1 antibody capable of recognizing the two isoforms (Neomarkers, Ab-1, DCS-6 antibody) indicated that MON cells expressed higher amount of 'b' than that of the 'a' isoform (Figure 5e , inset). MON cell pools transfected with 'a' isoform (a-MON) exhibited several fold increase in the Cyclin D1 protein levels, but those transduced with 'b' isoform (b-MON) exhibited moderate increase in the 'b' protein levels (Figure 5e , inset). The pools of cells transduced with either Cyclin D1a or D1b were subjected to an MTS assay after 2 or 3 days of exposure to 4-HPR, 4OH-Tam or the combination (Figure 5e ). Results of these experiments indicated that while MON cells transduced with empty vector exhibited survival kinetics very similar to that of wild type cells, pools of cells expressing Cyclin D1 isoforms were less susceptible to drugs. Notably, pools expressing the Cyclin D1b isoform were remarkably more resistant to the cytotoxic effect of drugs than those expressing Cyclin D1a isoform (Figure 5e ). When cyclin D1b protein was expressed, there was a moderate increase in IC 50 for 4-HPR (Figure 5e ). However, the IC 50 for combination of drugs was increased from 1.5 mM for the control cells (v-MON) to 10 mM for the Cyclin D1b-expressing cells (Figure 5e ). These results strongly suggested that expression of Cyclin D1b from a heterologous promoter in rhabdoid cells alters the therapeutic index and renders the cells less susceptible to the combination drug effect.
4-HPR and 4OH-Tam synergistically inhibit the growth of xenografted RTs in vivo
The above results strongly suggested that cyclin D1 is the therapeutic target of 4-HPR and 4OH-Tam in RTs.
To determine the effect of these drugs in vivo, we developed xenograft models of RTs. SCID mice were injected with rhabdoid cell lines to obtain xenografts. After the tumors were implanted and palpable (average volume B20 mm 3 ), the mice were randomized into four treatment groups (n ¼ 8) of control vehicle, 4-HPR (10 mg/kg), tamoxifen (2 mg/mouse) and combination 4-HPR (10 mg/kg) þ tamoxifen (2 mg/mouse). The mice were treated 5 days a week for 3 weeks, and then observed for additional 4 weeks. The results of these experiments indicated that, while tamoxifen and 4-HPR treatment significantly reduced the average tumor volume (Po0.01), the combination of drugs exhibited a clear synergistic effect on inhibiting the tumor growth (Po0.01, Figure 6A ). These results, for the first time, indicate that the combination of 4-HPR and tamoxifen inhibits RT growth in vivo.
In addition to the tumor volume, the possible toxic side effects of drugs at the specific dosage used were assessed by clinical observations of the mice during the treatment period and by gross pathological observation of all the vital organs at the termination of the study. We found that treatment of mice with single or combination of drugs had no significant effects either on the weights or on their clinico-pathological disposition (data not shown). However, we found that two out of eight mice died in the combination drug treatment Therapeutic targeting of cyclin D1 in rhabdoid tumors D Alarcon-Vargas et al arm while no mice died in the remaining groups, either treated with single drugs or not treated. Further studies are required to completely assess the toxicological profiles of combination drug therapy.
4-HPR and 4OH-Tam treatment decreases cyclin D1 levels in the RT xenografts
To determine if the reduction in the tumor volumes were associated with a decrease in cyclin D1 levels in vivo, we carried out immunohistochemical analysis of the tumors from four treatment groups at termination of the experiment, using a-cyclin D1 antibody. The results of these experiments indicated that control xenograft tumors exhibited pockets of clear and strong nuclear and cytoplasmic staining for cyclin D1 expression ( Figure 6B, panel a) . Tumors from the mice treated with tamoxifen alone retained a reduced level of positivity with cyclin D1 staining, consistent with the observation that the tumor growth reduction was not significant in this group ( Figure Together, these studies show that 4-HPR and tamoxifen are effective against RTs in vivo and that their effect is correlated with the downmodulation of cyclin D1 levels.
Discussion
Several studies have indicated that rhabdoid cells are resistant to commonly used chemotherapeutic agents that are known to be effective in several other malignancies Hilden et al., 2004) . The reason for lack of response to these potent chemotherapeutic agents is not clear. Hence, a systematic study is needed to develop specific, targeted strategies against RTs based on the sound understanding of the molecular mechanism of genesis of these tumors. Previously we demonstrated that cyclin D1 is a critical downstream target of INI1/hSNF5 and that it is required for the genesis of RTs in vivo (Zhang et al., 2002; Tsikitis et al., 2005) . In this report, we have found that inhibiting cyclin D1 either by RNAi or via drugs drastically inhibited growth and survival of RTs and cell lines. RNAi treatment of rhabdoid cells against Cyclin D1 was sufficient to induce G1 arrest and apoptosis. We have found that while 4-HPR alone is able to induce G1 arrest and apoptosis in all the rhabdoid cells at low mM concentrations, the combination of 4-HPR and 4OH-Tam has a synergistic effect and resulted in the decrease of IC 50 values for 4-HPR from about 15 to o40.2 mM. This is close to clinically achievable concentrations of 4-HPR and provides optimism for the potential use of these chemotherapeutic agents in treatment of RTs. In addition, we found that the combination treatment is synergistic in inhibiting growth and survival of rhabdoid cells in several survival and transformation assays and is correlated to synergistic induction of G1 arrest and apoptosis. Furthermore, we have demonstrated that the apoptosis was mediated by activation of caspase-3/7. Western analysis indicated a synergistic inhibition of cyclin D1 protein levels upon 4-HPR and 4OH-Tam treatment in rhabdoid cells, indicating an association with synergistic inhibition of cell growth by these drugs. These results are consistent with our observation that downmodulation of cyclin D1 by siRNA treatment alone is sufficient to induce G1 arrest and apoptosis in rhabdoid cells.
We further extended these cell culture observations to in vivo xenograft models. Our results, for the first time, demonstrated that 4-HPR and tamoxifen are effective in synergistically inhibiting the tumor growth in vivo. These results were associated with reduction in cyclin D1 expression in vivo, thus confirming our hypothesis that cyclin D1 is a key regulator of RT cell growth and survival in vitro and in vivo.
In addition to targeting cyclin D1, 4-HPR and 4OH-Tam could be acting via additional mechanisms. There could be favorable pharmacokinetic and pharmacodynamic interactions of these drugs in tumor cells (Appierto et al., 2001; Aoyama, 2002) . There could be a co-operative regulation of the same or distinct cellular targets by these drugs independent of their role in cell cycle progression (Favoni et al., 1998; Brockdorff et al., 2003; Mitsiades et al., 2003; Rousseau et al., 2003) . Other possible nonoverlapping mechanisms include the induction of ceramide-directed apoptosis, free radical generation and induction of NOS by these drugs (Maurer et al., 2000; Erdreich-Epstein et al., 2002; Simeone et al., 2002) . Further experiments are required to gain a in-depth mechanistic insight into the effect of 4-HPR and 4OH-Tam in rhabdoid cells.
Ours is the first report of specifically targeting a downstream effector of INI1/hSNF5, which was demonstrated to be required for rhabdoid tumorigenesis in vivo (Tsikitis et al., 2005) . We propose that either siRNA to cyclin D1 or combination chemotherapy using 4-HPR and 4OH-Tam could be effective in inhibiting RTs. The toxicities of 4-HPR and 4OH-Tam, both in the adult and pediatric population, are nonoverlapping and minimal (Singletary et al., 2002) . At this point, we find that the concentrations of 4OH-Tam required to achieve synergy appear to be high and may not be attained in adult patients. Nevertheless, in the pediatric population, where RTs are relevant, it has been reported that high doses of tamoxifen (100 mg/m 2 twice a day) can be administered with minimal toxicity (Pollack et al., 1997) . Furthermore, in cases where sustained high concentrations (X10 mM) of 4OH-Tam may still not be attained, alternative formulations of both tamoxifen and 4OH-Tam have been used that would result in the delivery of high concentration of these drugs directly to the tumor, such as by using a liposomal formulation (Zeisig et al., 2004) . Therefore, further preclinical and clinical studies to test the efficacy of these drugs in children may lead to the development of definitive therapeutic strategies against RTs with poor prognosis.
Materials and methods

Cell culture and materials
The RT cell lines (INI1À/À) used in this study are MON (Versteege et al., 1998) , G401 (ATCC # CRL-1441) and STM (Biegel et al., 1999) . Both 4-HPR (purchased from ONBIO, Ontario, Canada, CAS # 65646-68-6) and 4OH-Tam (Sigma Catalogue # H7904) were reconstituted in 100% ethanol, as a 10 mM solutions. 4-HPR used for animal studies was provided by Drs M Smith and J Zweibel at NCI.
RNA interference analysis
G401 or 293T cells were plated on six-well dishes to obtain 50% confluency the next day. Cells were transfected with siRNA, either scrambled control or cyclin D1 (SMARTpool Therapeutic targeting of cyclin D1 in rhabdoid tumors D Alarcon-Vargas et al CCND1 cat # M-003210, Upstate) using lipofectamine 2000 as per manufacturer's instructions. After 48 h, cells were trypsinized and divided into one 100 mm dish (5/6 of trypsinized sixwell) and one six-well (1/6 of trypsinized six-well). At 72 h post-trypsinization, cells from 100 mm dish were scraped, centrifuged at 1500 r.p.m. for 5 min at 41C, and lysed in RIPA buffer. In all, 100 mg of protein was run on an SDS-PAGE gel to assess the degree of cyclin D1 knockdown. The floating cells in the six-well were collected and pooled with adherent cells which were trypsinized and centrifuged at 1500 r.p.m. for 5 min at 41C. The collected cells were then subjected to FACS analysis as described below. The experiment was carried out three times. All cell cycle analyses were carried out in triplicate.
Analysis of single and combined drug effects on cell proliferation (MTS assay) The MTS assay was performed by plating aliquots of 3-5 Â 10 3 cells in 96-well plates treated with serial dilutions of each drug alone or with both drugs given simultaneously with a fixed concentration of one drug and an increasing concentration of the other, essentially as described (Wu et al., 2002) by using MTS assay kit (CellTiter 96 s AQ Non-Radioactive Cell Proliferation Assay Kit, Promega, Madison, WI, USA). Analysis of Fa and CI was determined using an equation described previously (Li et al., 2001) . The analysis of drug combination effects was performed by using the fractional product method and the Chou-Talalay equation,
for the determination of synergism and antagonism, where (Dx) 1 and (Dx) 2 in the denominators are the doses (or concentrations) for D 1 (4-HPR) and D 2 (4OH-Tam) alone that give x% inhibition, whereas (D) 1 and (D) 2 in the numerators are the doses of 4-HPR and 4OH-Tam in combination that also inhibited x% (Chou et al., 1991) . For drugs that are mutually nonexclusive in terms of having independent modes of action (a ¼ 1), CI o1, ¼ 1 and >1 indicate synergism, additive effect and antagonism, respectively.
Methylene Blue survival assay MON cells were seeded into 24-well plates at a density of 4-7 Â 10 5 cells per well in triplicate, and were incubated at 371C for 24 h, after which time point drugs (or control vehicle) were added to each well in triplicate. At the end of drug treatment, the media was aspirated and 200 ml of methylene blue (formulated in 1:1 ratio of 0.5% ethanol:water, v/v) was added to each well and incubated at room temperature for 1 h. The wells were then washed with double-distilled water. The plates were dried for the purpose of taking pictures. Finally, to each well, 1 ml of 1% SDS was added to solubilize cell membranes. The solution was mixed on a rotator at room temperature for 1 h and the OD of each well was read at 630 nM wavelength.
Anchorage-dependent (monolayer) clonogenicity assays Monolayer colony formation assay 1 was performed in the continuous presence of drugs, while assay 2 was performed in drug-free media after prior exposure to drugs, as described previously (Argiris et al., 2004) . In both the assays, the cells were treated for 48 h with the drug. For assay 1, the media was changed with the drug-containing media every 6 days. For assay 2, the media was changed every 6 days with drug-free media. For both assays 1 and 2, since the MON cells exhibited sparse, diffused colonies that were spread out, it was difficult to count the precise number of colonies. Therefore, photographs were taken as a visual record of the drug effect.
Anchorage-independent colony formation or soft agar growth assay First base plates were made by adding 3 ml of 2 Â RPMI 1640 to each 60 mm dish and incubated at 371C overnight. MON cells were mixed with RPMI 1640 supplemented with the same components in the presence of either 4-HPR, 4OH-Tam, both drugs or vehicle, and then plated on top of the base at a density of 2 Â 10 4 cells/60 mm dish in triplicate. The cells were incubated for 10-15 days. Big clusters were scored as colonies and small clusters of few cells (p6) and single cells were scored as single cells. Five microscopic fields ( Â 30) of each dish were scored, and the colony formation percentage was calculated by dividing the number of colonies by the total number of colonies plus single cells. Final results were expressed as percentages of untreated controls.
Cell cycle analysis and apoptosis analysis FACS analysis was used to determine the percentage of cells at various stages of the cell cycle as described previously with minor modifications (Zhang et al., 2002) . Apoptosis was assessed either by sub-G1 population gating by FACS or by analysis of activation of caspase-3/7 using the Caspase-Glo TM 3/7 assay (Promega, Cat# G8090). Cells were prepared as described above for the MTS assay in an opaque 96-well microtiter plate. After 24-48 h of treatment with drug(s), cells were incubated in 200 ml/well mixed medium (50% medium and 50% Caspase-Glot reagent) for 30 min to 3 h. The relative light units (RLU) were read using a microtiter plate reader (Wallac-Victor, 1420 Multilabel Counter, Perkin-Elmer). The results were expressed as RLU per 10 000 cells per well.
Immunoblot analysis
This assay was performed using a routine laboratory protocol as previously described using the chemiluminescence detection method (Zhang et al., 2002) . The following antibodies were used: polyclonal a-cyclin D1 Ab-3 (NeoMarkers, Cat# RB-010-P0), monoclonal a-cyclin D1 DCS-6 (NeoMarkers, Cat# MS-210-P1), a-b-actin (Sigma Cat# A5441) and a-tubulin-a (Sigma, Cat # T5168).
Statistical analysis
Descriptive statistical parameter tests (including tests for normality using the Kolmogorov-Smirnov test) for cell survival, cell cycle and apoptosis numbers for each data category or group (e.g., controls, 4-HPR-treated etc.) were performed using GraphPad Prism version 4.00 for Macintosh, GraphPad Software, San Diego, CA, USA, www.graphpad. com. Outlier analysis of each data set was performed using the Grubb's test; however, all data points (including outliers) were included in the analysis for significance. For multiple category comparison of three or more data categories (e.g., 4OH-Tamversus 4-HPR-versus 4-HPR-and 4OH-Tam-treated cell lines), one-way ANOVA with Dunnett's post test (nonparametric) was performed. The same software was used for paired and unpaired comparisons using t-statistic (one tailed or two tailed), where equal variance in data between categories was shown or assumed.
Testing the effect of 4-HPR and Tamoxifen on xenografted RTs in vivo RT xenografts were developed by inoculating about 10 7 G401 cells into the right flank of SCID mice. After the tumors were implanted and reached a palpable size (average of B20 mm 3 in each group), the mice were randomized into four treatment groups, with eight animals per group, consisting of: (i) control; (ii) 4-HPR alone (10 mg/kg); (iii) tamoxifen (2 mg/mouse in Therapeutic targeting of cyclin D1 in rhabdoid tumors D Alarcon-Vargas et al corn oil) alone and (iv) 4-HPR (10 mg/kg) þ tamoxifen (2 mg/ mouse). These animals were injected with either tamoxifen subcutaneously or with 4-HPR intraperitonially or both. The control animals were treated with both vehicles. Tamoxifen was prepared by dissolving the required amount in preheated corn oil, and a fine suspension of 1 mg/ml 4-HPR in 0.5% ethanol þ 1.65 mg/ml BSA in saline was used. Tumors were measured by using a digital vernier calipers manually and tumor volumes were calculated assuming tumors to be spherical using the formula (0.5lhw).
Immunohistochemical analysis
Paraffin sections, 4 mm thick, taken on charged slides were de-paraffinized in xylene and hydrated with graded alcohols and distilled water. Antigen retrieval was performed in citrate buffer (pH 6.0) using a microwave oven for 8 min. This was followed by blocking of endogenous peroxidase activity with Peroxo-block s (Zymed, San Francisco, CA catalogue # 00-2015). After rinsing the slides in Tris-buffered saline, the slides were incubated overnight with cyclin D1 antibody (Cell Marque, AR, catalogue # CMC635, dilution 1:50). The antigen-antibody reaction was visualized by Envision Kit (DAKO, CA, Catalogue # K4000) and diaminobenzidine (DABplus s , Dako, Carpentaria, CA, catalogue # K3467) as the chromogen. Sections were counterstained with hematoxylin (Vector Laboratories, Burlingame, CA catalogue # H3404) cleared in alcohol and xylene and mounted with Histomount (Zymed, San Francisco, CA, catalogue # 00-8030). The IHC slides were analysed by pathologist author, BA.
Generation of MON stable cells expressing Cyclin D1-FLAG isoforms
The transducing retroviral vectors expressing Cyclin D1a and Cyclin D1b isoforms were obtained by subcloning the inserts from the corresponding pMXpuro-cyclin D1 vectors into pBabe-Puro-FLAG retroviral vector (Grace Cheng, unpublished) . MON cells stably expressing either cyclin D1a-FLAG. or Cylcin D1b-FLAG proteins were generated by infecting with each of the transducing vectors, pBabe-puro-FLAG (empty vector control), pBabe-puro-Cyclin D1a-FLAG, or pBabe-puro Cyclin D1b-FLAG, and selecting for puromycinresistant colonies (RPMI containing 1 mg/ml of puromycin, Sigma, Catalogue # P8833). The positive transfectants of MON cells were pooled and subjected to further analysis.
